NCT07827612Not yet recruitingPhase 2
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC). Safety tests will also be conducted. For each participant, the study will last up to 5 years.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 161 (estimated)
- First submitted
- 15 Sept 2026
- Start date
- Dec 2026
- Primary completion date
- Jul 2028
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Bladder cancer
- NCT number
- NCT07827612
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 161
- From Dec 2026 to the primary completion date, Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All Participants
- Have had a prior positive urine cytology within 6 weeks of first day of treatment.
- Have received prior local instillation (for example, intravesical chemotherapy, Bacillus Calmette-Guerin, Jelmyto) therapy within 8 weeks of the first day of treatment.
Other illness
- Cohort A
- Have synchronous UTUC disease.
- Have presence of, or history of, high-grade urothelial carcinoma within 3 years of the first day of treatment, or presence of, or history of, carcinoma in situ.
- Cohort B
- Have presence of bladder tumors at the time of enrollment.
- Have presence of, or history of, high-grade urothelial carcinoma or carcinoma in situ.
Who the study is looking for
- All Participants:
- Have a PS of 0 to 2 on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale
- Cohort A
- Have histologically confirmed LG NMIBC.
- Have LG IR NMIBC at time of screening
- Have a documented qualifying fibroblast growth factor receptor 3 protein (FGFR3) mutation or fusion
- Cohort B
- Have histologically confirmed LG UTUC.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Carolina Urologic Research Center Coordinator of this site? Confirm its status | Myrtle Beach | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.